Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Free Cash Flow (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Free Cash Flow for 17 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 60.5% to $1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.8 billion through Dec 2025, down 7.87% year-over-year, with the annual reading at $12.8 billion for FY2025, 7.87% down from the prior year.
  • Free Cash Flow for Q4 2025 was $1.6 billion at Bristol Myers Squibb, down from $6.0 billion in the prior quarter.
  • The five-year high for Free Cash Flow was $6.0 billion in Q3 2025, with the low at $1.6 billion in Q4 2025.
  • Average Free Cash Flow over 5 years is $3.3 billion, with a median of $3.5 billion recorded in 2022.
  • The sharpest move saw Free Cash Flow soared 136.33% in 2021, then crashed 60.5% in 2025.
  • Over 5 years, Free Cash Flow stood at $3.7 billion in 2021, then fell by 20.79% to $3.0 billion in 2022, then soared by 32.5% to $3.9 billion in 2023, then rose by 3.54% to $4.1 billion in 2024, then crashed by 60.5% to $1.6 billion in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $1.6 billion, $6.0 billion, and $3.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.